Evidence map›Paper›PMID 26815661›Full record

ArticleJournal of molecular histology2016

Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.

Mehmet Kanter, Gulay Turan, Ceyda Usta, Akin Usta, H Hasan Esen, Lema Tavlı, Cetin Celik, Yusuf Demirkol, Betül Kanter

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Mehmet KanterDepartment of Histology and Embryology, Faculty of Medicine, Istanbul Medeniyet University, 34710, Istanbul, Turkey. mkanter65@yahoo.com.
Gulay TuranDepartment of Pathology, Faculty of Medicine, Selcuk University, Konya, Turkey.
Ceyda UstaGoztepe Education and Research Hospital, Clinics of Gynecology and Obstetrics, Istanbul Medeniyet University, Istanbul, Turkey.
Akin UstaGoztepe Education and Research Hospital, Clinics of Gynecology and Obstetrics, Istanbul Medeniyet University, Istanbul, Turkey.
H Hasan EsenDepartment of Pathology, Faculty of Medicine, Selcuk University, Konya, Turkey.
Lema TavlıDepartment of Pathology, Faculty of Medicine, Selcuk University, Konya, Turkey.
Cetin CelikDepartments of Gynecology and Obstetrics, Faculty of Medicine, Selcuk University, Konya, Turkey.
Yusuf DemirkolFaculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Betül KanterFaculty of Medicine, Medical University, Sofia, Bulgaria.
Istanbul Medeniyet University · TRSelçuk University · TRMedical University of Sofia · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most prevalent malignant ovarian neoplasms are epithelial ovarian cancers which is the most common cause of death among all gynecologic malignancies and a result of complex interaction of multiple oncogenes and tumor suppressor genes. The aim of this study was to evaluate expression of survivin and cycline D1 biomarkers in mucinous ovarian neoplasms and their correlations with clinicopathological variables in mucinous ovarian cancers. We analyzed pathological specimens of 98 patients with benign (n = 34), borderline (n = 22) and malignant (n = 42) mucinous ovarian neoplasms. Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded specimens. Immunohistochemical analysis revealed that survivin and cyclin D1 expressions were located primarily in the nucleus of ovarian tumor cells and relatively weaker cytoplasmic staining. Survivin expression was significantly higher in malignant tumors (88.1 %) than those found in borderline (18.2 %) and benign tumors (8.8 %) (p < 0.001). Similarly, higher cyclin D1 expression was observed in malignant tumors (100 %) compared to borderline (36.4 %) and benign tumors (5.9 %) (p < 0.001). Expression of all biomarkers analyzed significantly and gradually increased from benign to borderline and borderline to malignant mucinous tumors. In terms of clinicopathological variables, tumor grade, FIGO stage and lymph node methastasis were associated with the expression of both biomarkers. Whereas age exhibited no different correlations in mucinous ovarian cancers. The expressions of survivin and cycline D1 are positively correlated with the malignant potential of mucinous ovarian neoplasms.

Indexed as

AdolescentAdultAgedAged, 80 and overCell NucleusCyclin D1FemaleHumansInhibitor of Apoptosis ProteinsMiddle AgedNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsSurvivinYoung AdultBIRC5 protein, humanCCND1 protein, humanCyclin D1Inhibitor of Apoptosis ProteinsSurvivinCycline D1Immunohistochemical analysisMucinousOvarian neoplasmsSurvivin

Identifiers

PMID26815661
OpenAlexW2299670922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.